Floatz logo

Anti-Cd19/Cd22 Car-T Cells

B Cell Lymphoma

Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyCell therapyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Zanubrutinib
The First Affiliated Hospital of Soochow University
Phase 4BBB
Chimeric Antigen Receptor Modified T Cells Infusion
The First Affiliated Hospital of Soochow University
Phase 2/3BB
VINCRISTINE SULFATE
The First Affiliated Hospital of Soochow University
Phase 4BB
Cart-19 And 20 Cells
Henan Cancer Hospital
Phase 2BB
Cart-19 Cells
Shenzhen BinDeBio Ltd.
Phase 2/3BB

View all 50 →

Same molecule, other indications

Anti-Cd19/Cd22 Car-T Cells is also rated in:

Acute Lymphobkastic LeukemiaDormant
B
Indicative ·
57 / 100
View asset →
CAR T Cell TherapyDormant
B
Indicative ·
57 / 100
View asset →
Auto Stem Cell TransplantDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →